TRIMTECH Therapeutics

TRIMTECH Therapeutics is a biotechnology company developing small-molecule degraders that selectively remove disease-causing protein aggregates while preserving the functional, non-aggregated forms of the same proteins.

The platform is built on research into the E3 ubiquitin ligase TRIM21, conducted over nearly two decades at the MRC Laboratory of Molecular Biology and UK Dementia Research Institute at Cambridge.

The company's pipeline targets neurodegenerative and inflammatory disorders including Alzheimer's and Huntington's disease.